CCDC 117922: Experimental Crystal Structure Determination

W. Grell(Boehringer Ingelheim (Germany)), P. Muller, Robert Sauter(Boehringer Ingelheim (Germany)), E. Rupprecht(Boehringer Ingelheim (Germany)), Herbert Nar(Boehringer Ingelheim (Germany)), Rudolf Hurnaus(Boehringer Ingelheim (Germany)), P. Luger, Helmut Wittneben(Pharmazeutische Fabrik Dr. Reckeweg (Germany)), G. Griss
The Cambridge Structural Database
January 1, 1999
10.5517/cc3ypyn
Cited by 0

Related Papers

A specific antidote for dabigatran: functional and structural characterization
|Blood|2013|562
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383
8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
|Journal of Medicinal Chemistry|2007|285